Clinical Trial: Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07250477) titled 'Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer' on Nov. 18.

Brief Summary: This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer Stage IIIC Non-small Cell Lung Cancer Stage IV Non Small Cell Lung Cancer Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Unresectab...